HIV-Induced Abnormalities in Myelopoiesis and their Recovery Following Antiretroviral Therapy

Author(s): Andrea Costantini, Simona Giuliodoro, Luca Butini, Guido Silvestri, Pietro Leoni, Maria Montroni.

Journal Name: Current HIV Research

Volume 8 , Issue 4 , 2010

Become EABM
Become Reviewer


HIV-1 infection is associated with hematologic abnormalities including defective myelopoiesis. Most studies of myelopoiesis during HIV-1 infection were performed using unfractionated bone marrow-derived mononuclear cells, thus resulting in significant inter-individual variability in the numbers of cultured precursors. Here we evaluated the myelopoietic potential of circulating CD34+ progenitors by conducting a longitudinal analysis of antiretroviral therapy (ART)-induced changes of colony forming units-granulocyte and monocyte (CFU-GM) growth. Twelve HIV-infected individuals were studied longitudinally before and after initiation of ART (i.e. at a time when plasma HIV-RNA levels had become undetectable); thirty-one HIV-uninfected healthy individuals were enrolled as controls. Peripheral bloodderived CD34+ progenitors were purified by immunomagnetic sorting, and cultured in methylcellulose-based medium containing stem cell factor, granulocyte-monocyte colony-stimulating factor and interleukin-3. ART-induced changes in the proportion of CD8+ T cells expressing surface HLA-DR were also evaluated. We found that CFU-GM levels were increased in untreated HIV-infected individuals when compared to uninfected controls but declined significantly following ART, in parallel with the decline of HIV-RNA levels in plasma and with the down-regulation of HLA-DR expression on CD8+ T cells. These findings suggest that, in untreated HIV-infected individuals, chronic inflammation and/or immune activation is associated with defective myelopoiesis and accumulation of myeloid precursors. ART-induced suppression of HIV-1 replication is associated with normalization of CFU-GM levels.

Keywords: Myelopoiesis, HIV-1 infection, CD34+ hematopoietic stem cells, antiretroviral therapy, CFU-GM

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [336 - 339]
Pages: 4
DOI: 10.2174/157016210791208604
Price: $58

Article Metrics

PDF: 1